The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study

The efficacy of afatinib in combination with bevacizumab in untreated advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma is currently unclear. We sought to investigate the efficacy of this combination through a multicenter observational analysis. Data for 57 patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Ping-Chih, Huang, Chun-Yao, Wang, Chin-Chou, Kuo, Scott Chih-Hsi, Chu, Chia-Hsun, Tung, Pi-Hung, Huang, Allen Chung-Cheng, Wang, Chih-Liang, Chiu, Li-Chung, Fang, Yueh-Fu, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690705/
https://www.ncbi.nlm.nih.gov/pubmed/33113888
http://dx.doi.org/10.3390/ph13110331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690705/
https://www.ncbi.nlm.nih.gov/pubmed/33113888
http://dx.doi.org/10.3390/ph13110331

Ejemplares similares